Calidi Biotherapeutics Inc
Follow $CLDI
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $CLDI by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredsnapshot unavailable for CLDI. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is CLDI moving today?
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
CLDI overview
Related filings and maps
Congress activity in CLDI
No receipt-qualified Congressional disclosure is present for CLDI in the cached public ledger.
CLDI contract awards, year to date.
Public federal awards linked to this ticker.
CLDI lobbying filings, year to date.
Registered lobbying filings matched to Calidi Biotherapeutics Inc.